Change in Demoralization Scale (DSII) by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Annual number of outpatient visits in all eyes. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Time course of best-corrected visual acuity (BCVA) in all eyes. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Annual number of outpatient visits in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Time course of central retinal thickness (CRT) in all eyes. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Annual treatment frequencies in all eyes. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Annual treatment frequencies in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

الموضوعات:

Preoperative background characteristics of the patients. حسب Yasuyuki Sotani (20114144)

الموضوعات: